Citadel Advisors
YARW

Citadel Advisors’s Yarrow Bioscience YARW Stock Holding History

Citadel Advisors’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Hold
0
– -$60 – 15593
2022
Q4 		– Hold
0
– – – 14780
2022
Q3 		– Sell
-51
Closed -$18K – 13708
2022
Q2 		$18K Sell
51
-66
-56% -$27.7K ﹤0.01% 12442
2022
Q1 		$69K Buy
117
+23
+24% +$13.7K ﹤0.01% 12590
2021
Q4 		$86K Buy
94
+46
+96% +$49.4K ﹤0.01% 12861
2021
Q3 		$60K Buy
48
+11
+30% +$21.3K ﹤0.01% 13268
2021
Q2 		$116K Sell
37
-30
-45% -$119K ﹤0.01% 12780
2021
Q1 		$415K Buy
+67
New +$486K ﹤0.01% 10089

Other funds holding YARW

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Citadel Advisors's YARW Position: Q2 2026 in Review

Citadel Advisors reduced its Yarrow Bioscience (YARW) stake by 8.9% in Q2 2026, selling an estimated $29.8K and leaving 9,369 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #11086.

Citadel Advisors first reported a position in YARW in Q1 2018 and has held it in 21 quarters since. The position peaked at $4.12M in Q4 2024. 40 funds tracked by Wall St. Rank hold YARW as of Q2 2026.

  • Citadel Advisors held 9,369 shares of Yarrow Bioscience worth $305K as of Q2 2026.
  • Citadel Advisors sold 920 Yarrow Bioscience shares in Q2 2026, an estimated $29.8K.
  • Yarrow Bioscience made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11086 holding.
  • Citadel Advisors first reported a position in Yarrow Bioscience in Q1 2018 and has held it in 21 quarters since.
  • Citadel Advisors's Yarrow Bioscience position peaked at $4.12M in Q4 2024.
  • 40 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.